ASND - Ascendis Pharma AS - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ASND is currently covered by 14 analysts with an average price target of $250.57. This is a potential upside of $60.22 (31.64%) from yesterday's end of day stock price of $190.35.

Ascendis Pharma AS's activity chart (see below) currently has 234 price targets and 218 ratings on display. The stock rating distribution of ASND is 92.41% BUY and 7.59% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 54.51% with an average time for these price targets to be met of 352.95 days.

Highest price target for ASND is $289, Lowest price target is $153, average price target is $220.93.

Most recent stock forecast was given by JESSICA FYE from JPMORGAN on 29-Jul-2025. First documented stock forecast 23-Feb-2015.

Currently out of the existing stock ratings of ASND, 73 are a BUY (92.41%), 6 are a HOLD (7.59%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$254

$80.5 (46.40%)

$245

10 days ago
(29-Jul-2025)

21/24 (87.5%)

$90.68 (55.52%)

155

Buy

$243

$69.5 (40.06%)

$207

28 days ago
(11-Jul-2025)

6/12 (50%)

$68.04 (38.89%)

536

Buy

$250

$76.5 (44.09%)

$250

1 months 5 days ago
(03-Jul-2025)

19/22 (86.36%)

$75.82 (43.53%)

221

Buy

$224

$50.5 (29.11%)

$180

1 months 26 days ago
(13-Jun-2025)

3/11 (27.27%)

$53.2 (31.15%)

789

Buy

$216

$42.5 (24.50%)

$201

1 months 30 days ago
(09-Jun-2025)

11/14 (78.57%)

$42.85 (24.75%)

268

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ASND (Ascendis Pharma AS) average time for price targets to be met?

On average it took 352.95 days on average for the stock forecasts to be realized with a an average price target met ratio 54.51

Which analyst has the current highest performing score on ASND (Ascendis Pharma AS) with a proven track record?

PAUL CHOI

Which analyst has the most public recommendations on ASND (Ascendis Pharma AS)?

Paul Choi works at GOLDMAN SACHS and has 6 price targets and 5 ratings on ASND

Which analyst is the currently most bullish on ASND (Ascendis Pharma AS)?

Derek Archila with highest potential upside - $115.5

Which analyst is the currently most reserved on ASND (Ascendis Pharma AS)?

Tiago Fauth with lowest potential downside - -$84.5

Ascendis Pharma AS in the News

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Ascendis Pharma – Q2 2025 revenue of €103.0 million for YORVIPATH®and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® (lonapegsomatropin-tcgd) approved in the U.S. for treatment of adults with growth hormone deficiency; first of many planned...

CGGR's Underlying Holdings Imply 10% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Capital Group Growth ETF (Symbol: CGGR), we found...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?